FDA Gives Instructions to Manufacturers on Next COVID-19 Vaccines

Food and Drug Administration officials said they will make a decision at a later date.

A health care worker in New York prepares a vaccine in a file photograph. Michael M. Santiago/Getty Images

The Food and Drug Administration (FDA) on May 22 advised manufacturers to update formulations for their COVID-19 vaccines.

The FDA said in a statement that it told Pfizer, Moderna, and Novavax that “the COVID-19 vaccines for use in the United States beginning in fall 2025 should be monovalent JN.1-lineage-based COVID-19 vaccines,” preferably targeting the JN.1 subvariant LP.8.1.